As shown in Figure 7B-C, no statistically significant difference was found in the percentage and number per gram tumor of CD45- CD31+ ECs among the lena, the hRT, and the hRT/lena treatment groups in the non-irradiated secondary tumor. This evidence concerns the gene PTPRC and neoplasm.